PatientF3P1: Female, 3 months diagnosis, Multiracial (maternal European and Native American and paternal Czechoslovakian, German, and Australian)

CasePresentingHPOs: HP:0004755, HP:0001290 (Supraventricular tachycardia, Generalized hypotonia)

CaseAddInfo: Proband

PatientF3P3: Male, 6 years report, Multiracial (maternal European and Native American and paternal Czechoslovakian, German, and Australian)

CaseAddInfo: Presymptomatic, sibling of F3P1 and child of F3P2, has a presymptomatic sister age 4, F3P4, with the same GAA mutations, Author states variants are in trans

Case22HPOsFreeText: 20 mg/kg GAA treatment, GAA activity at 7 mU/U hexosaminidas, GAA activity at 25% lower limit of normal

CaseAddInfo: Late Onset Pompe Disease

CaseGenotypingMethod: Method not described, only that the diagnosis was "confirmed … based on 2 GAA gene mutations"

Variant1: NM_000152.4:c.-32-13T>G

ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 https://gnomad.broadinstitute.org/variant/17-78078341-T-G

Variant2: NM_000152.4:c.2608C>T (p.Arg870Ter)

ClinVar: 189009 https://www.ncbi.nlm.nih.gov/clinvar/variation/189009/

gnomAD: European (Non-Finnish) 4.888e-5, Overall 2.662e-5 https://gnomad.broadinstitute.org/variant/17-78092118-C-T

CaseAddInfo: Patient is compound heterozygous for these variants

Case27: Male, 71 years report

HPOsFreeText: 0.3 years of ERT completed, 6 Minute Walking Test at 348 meters, Forced Vital Capacity at 53%

GenotypingMethod: GAA Gene Sequencing

Variant1: NM_000152.4:c.-32-13T>G

ClinVar: 4027 http://www.ncbi.nlm.nih.gov/clinvar/variation/4027

gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G

Variant2: NM_000152.4:c.2608C>T (p.Arg870Ter)

ClinVar: 189009 https://www.ncbi.nlm.nih.gov/clinvar/variation/189009/

gnomAD: European (Non-Finnish) 4.888e-5, Overall 2.662e-5 http://gnomad.broadinstitute.org/variant/17-78092118-C-T

CaseAddInfo: Late Onset Pompe Disease

Case78

HPOsFreeText: See Group Phenotypes

CasePreviousTesting: Sanger sequencing

CaseMethod1: Sanger sequencing and PCR Amplification

CaseMethod2: Whole Exome Sequencing (WES)

CaseGenotypingMethod: Patients were previously confirmed with Pompe disease by Sanger sequencing to capture the pathogenic variants. The process was repeated as part of the study taking care to amplify the coding regions and exon/intron boundaries to compare with the WES results afterwards.

Variant1: NM_000152.4:c.2608C>T (p.Arg870*)

ClinVar: 189009 https://www.ncbi.nlm.nih.gov/clinvar/variation/189009/

gnomAD: European (Non-Finnish) 4.888e-5, Overall 2.662e-5 http://gnomad.broadinstitute.org/variant/17-78092118-C-T

Variant2: NM_000152.4:c.-32-13T>G

ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G

CaseAddInfo: Adult Late Onset Pompe Disease

Case18: Female, Unknown years onset, Unknown years diagnosis, 25 years report

CasePresentingHPOs: HP:0003325, HP:0003327, HP:0003236 (Limb-girdle muscle weakness, Axial muscle weakness, Increased serum CK)

CaseAddInfo: Late-Onset Pompe Disease

Case#: 4, age 24, age 18 (report)

DiseaseAssertion: Pompe Disease

FamilyInfo: Family 4, no further information

CasePresenting HPOs:HP:0012378, HP:0003546, HP:0001324 (fatigue, exercise intolerance, muscle weakness)

CaseHPOFreeText: vacuolar myopathy biopsy PAS +

CaseNotHPOs: N/A

CaseNotHPOFreeText: N/A

CasePreviousTesting: single gene sequencing/analysis, 40.54 NaG/AaGIA, 90.54% inhibition of GAA; NaG/AaGIA above 40 and %INH above 87 are in the affected range

Variants:

Variant 1:NM_000152.5(GAA):c.2608C>T (p.Arg870Ter)

ClinVar: 189009

Variant 2: not reported

ParentalGenotypes: N/A

PreviouslyPublished: N/A

Case#: Patient 1, female, 2.5 months of age at diagnosis, Hispanic

DiseaseAssertion: Pompe disease

FamilyInfo: N/A

CasePresentingHPOs: HP:0001638, HP:0032988, HP:0001252, HP:0001270, HP:0002015, HP:0012378

(Cardiomyopathy, Persistent head lag, Muscular hypotonia, Motor delay, Dysphagia, Fatigue)

CaseHPOFreeText: NG tube feeding was left after Enzyme Replacement Therapy (ERT).

Cardiac status at base line was 160 LVMI g/m^2, after ERT IT WAS 81 LVMI g/m^2

Patient needed oxygen at baseline, no respiratory support at ERT.

one episode of Infusion Associated Reactions (IARs) to ERT.

CaseNotHPOs: N/A

CaseNotHPOFreeText: N/A

CasePreviousTesting:

Variant 1: NM_000152.5(GAA):c.2608C>T (p.Arg870Ter)

ClinVar: 189009

CAID: CA274250

gnomAD: Highest population MAF= 0.00004888 (European non-Finnish)

ParentalGenotype:N/A

PreviouslyPublished:N/A